Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer
Status:
Recruiting
Trial end date:
2023-07-27
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well atezolizumab in combination with chemotherapy works in
treating patients with anaplastic or poorly differentiated thyroid cancer. Immunotherapy with
monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread. Vemurafenib and
cobimetinib may stop the growth of cancer cells by blocking some of the enzymes needed for
cell growth. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of
cancer cells to grow and spread. Drugs such as nab-paclitaxel and paclitaxel work in
different ways to stop the growth of cancer cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. This trial is being done to see if
atezolizumab in combination with chemotherapy works better in treating patients with
anaplastic or poorly differentiated thyroid cancer compared to standard treatments.